3SBio (HK:1530)
:1530
Top Page
3SBio
(1530)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$25.00
▼(-1.50% Downside)
Action:DowngradedDate:11/22/25
3SBio's overall stock score is driven by its strong financial performance, characterized by robust revenue and profit growth. However, technical indicators suggest potential short-term weakness, and the high valuation may limit upside potential. The absence of earnings call data and corporate events means these factors do not influence the score.
Positive Factors
Consistent Revenue & Profit Growth
Consistent top-line and bottom-line growth through 2019–2024 demonstrates expanding commercial traction in biologics. Sustained revenue and profit growth supports predictable cash generation to fund R&D, manufacturing scale-up and market penetration over the next several quarters.
Negative Factors
Inconsistent Free Cash Flow
Volatile free cash flow driven by uneven capex and investing cash flows creates uncertainty in internal funding. That variability can force external financing, delay R&D/commercial projects, or constrain dividend/payout policies, weakening financial flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue & Profit Growth
Consistent top-line and bottom-line growth through 2019–2024 demonstrates expanding commercial traction in biologics. Sustained revenue and profit growth supports predictable cash generation to fund R&D, manufacturing scale-up and market penetration over the next several quarters.
Read all positive factors
3SBio (1530) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$64.41B
Dividend Yield0.95%
Average Volume (3M)31.12M
Price to Earnings (P/E)9.6
Beta (1Y)0.89
Revenue Growth7.51%
EPS Growth44.09%
CountryHK
Employees5,577
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3.31
Shares Outstanding2,538,005,400
10 Day Avg. Volume32,899,411
30 Day Avg. Volume31,124,824
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.91
Price to Sales (P/S)1.54
P/FCF Ratio6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$35.42Price Target Upside39.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.15
Revenue Forecast (FY)HK$10.56B
3SBio Business Overview & Revenue Model
Company Description
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-in...
How the Company Makes Money
3SBio generates revenue through multiple streams, primarily by selling its proprietary biopharmaceutical products to hospitals and healthcare providers in China. The company earns significant income from the sales of its key products, including it...
3SBio Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.07B | 9.11B | 7.82B | 6.86B | 6.38B | 5.59B |
| Gross Profit | 7.75B | 7.83B | 6.64B | 5.67B | 5.28B | 4.52B |
| EBITDA | 2.69B | 2.93B | 2.53B | 2.75B | 2.26B | 1.68B |
| Net Income | 2.36B | 2.09B | 1.55B | 1.92B | 1.65B | 835.79M |
Balance Sheet | ||||||
| Total Assets | 23.83B | 24.21B | 23.63B | 21.99B | 19.21B | 17.68B |
| Cash, Cash Equivalents and Short-Term Investments | 6.46B | 5.79B | 5.99B | 7.01B | 4.70B | 4.36B |
| Total Debt | 1.87B | 3.55B | 4.84B | 4.52B | 2.63B | 2.91B |
| Total Liabilities | 4.89B | 6.18B | 7.11B | 6.59B | 4.55B | 4.58B |
| Stockholders Equity | 16.32B | 15.44B | 14.03B | 12.96B | 12.23B | 10.69B |
Cash Flow | ||||||
| Free Cash Flow | 1.67B | 2.24B | 1.38B | 1.21B | 432.57M | 363.09M |
| Operating Cash Flow | 2.11B | 3.20B | 2.08B | 2.18B | 1.58B | 1.34B |
| Investing Cash Flow | -738.83M | -1.36B | -1.35B | -3.72B | -1.29B | -1.87B |
| Financing Cash Flow | -1.28B | -2.25B | -352.98M | 763.22M | -481.12M | 1.55B |
3SBio Technical Analysis
Positive
25.38
Price Trends
22.85
Positive
25.68
Negative
27.26
Negative
Market Momentum
0.48
Negative
60.80
Neutral
73.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1530, the sentiment is Positive. The current price of 25.38 is above the 20-day moving average (MA) of 22.52, above the 50-day MA of 22.85, and below the 200-day MA of 27.26, indicating a neutral trend. The MACD of 0.48 indicates Negative momentum. The RSI at 60.80 is Neutral, neither overbought nor oversold. The STOCH value of 73.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1530.
3SBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$64.41B | 9.63 | 14.85% | 0.95% | 7.51% | 44.09% | |
66 Neutral | HK$27.73B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
63 Neutral | HK$144.73B | 11.12 | 10.55% | ― | 16.90% | 63.11% | |
61 Neutral | HK$113.21B | 43.78 | 11.85% | 1.40% | 13.69% | 50.71% | |
61 Neutral | HK$158.77B | -762.50 | 4.82% | ― | 52.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.58B | -22.62 | -14.53% | ― | 38.56% | 48.26% |
* Healthcare Sector Average
HK:1530
3SBio
25.38
14.27
128.44%
HK:1177
Sino Biopharmaceutical
6.33
2.96
87.67%
HK:1801
Innovent Biologics
91.50
49.45
117.60%
HK:2269
Wuxi Biologics (Cayman)
34.98
17.16
96.30%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.18
99.85%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.60
50.50
193.49%
3SBio Corporate Events
3SBio Completes Share Placement to Boost R&D and Global Expansion
Dec 9, 2025
3SBio Inc. has successfully completed the placement of 105,169,500 new shares, raising approximately HK$3,086.84 million. The proceeds will be used primarily for research and development expenditures, including advancing clinical research on innov...
3SBio Announces Strategic Share Placement to Raise HK$3 Billion
Dec 2, 2025
3SBio, a company incorporated in the Cayman Islands, has announced a strategic move to place 105,169,500 new shares under a general mandate. The shares will be placed at a price of HK$29.62 per share, representing a discount to recent market price...
3SBio Announces Proposed Spin-Off and Listing of Mandi Inc.
Nov 20, 2025
3SBio, a company incorporated in the Cayman Islands, has announced its intention to spin-off and separately list its subsidiary, Mandi Inc., on the Main Board of the Stock Exchange of Hong Kong. This strategic move involves distributing all shares...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.